Key rate of Russia’s Central BankBusiness & Economy July 27, 15:59
Decision to strip Saakashvili of Ukrainian citizenship ‘not Kremlin’s problem’Russian Politics & Diplomacy July 27, 15:43
NHL three-time Stanley Cup winner Malkin still hopes to play for Russia at 2018 GamesSport July 27, 15:33
Brazilian football team’s staff kick off Russian language practice ahead of 2018 World CupSport July 27, 14:48
Kremlin explains why commenting on new US envoy pick would be inappropriate nowRussian Politics & Diplomacy July 27, 14:37
Kremlin comments on EU sanctions against RussiaRussian Politics & Diplomacy July 27, 14:36
Russian, Finnish presidents to discuss stability, security in Baltic regionWorld July 27, 14:24
Putin appoints Russia’s permanent representative to UNRussian Politics & Diplomacy July 27, 13:41
CEO vows Shell will strive to honor its Nord Stream 2 commitmentsBusiness & Economy July 27, 13:31
LA JOLLA, California, Oct. 31, 2014 /PRNewswire/ -- Human Longevity, Inc. (HLI), a biological data-driven human health technology and cell therapy company, today announced the addition of Barry Merriman, Ph.D., as Vice President of Global Technology Assessment and Paul Mola, M.S. as Head of Global Solutions. The two will work together in HLI's new Global Solutions Initiative to seek strategic business opportunities worldwide.
HLI's Global Solutions Initiative is aimed at business partnerships with a variety of customers including foreign governments, large national healthcare systems, and global disease or health-focused charities interested in undertaking population-scale genomic and personalized medicine initiatives. Dr. Merriman and Mr. Mola will engage with these entities to offer enterprise solutions, and services and business opportunities customized to empower and accelerate these projects. This includes access to HLI's comprehensive human biological database, coupled with the company's proprietary computational infrastructure and analytical software solutions.
"We are pleased to welcome Barry and Paul to the HLI team as they bring unique and varied scientific, technological and business expertise," said J. Craig Venter, PhD, HLI's Co-founder, Chairman, and Chief Executive Officer. "Their knowledge of the global genomics market, coupled with their strong scientific and technology backgrounds and ability to translate this experience into successful global partnerships will be invaluable to HLI."
Dr. Merriman commented, "My goal has always been to use science and technology to advance human health and longevity. HLI is unique in pursuing a complete and integrated approach to this, with the focus, resources and scale required for success, and with an endpoint of truly revolutionizing health care. I am very excited to work with leaders globally on ways for HLI to empower their efforts to improve health and solve disease in their populations."
Mr. Mola added, "HLI's focused investment to create an unmatched, end-to-end infrastructure for population scale projects will enable the most advanced clinical capabilities for solving some of the common diseases of aging. I am pleased to be joining HLI and am eager to help the company realize its mission of comprehensive integration of genomic advances, cellular therapeutics, and health information technology, to create an unprecedented knowledge base of patient biological data to effect health care change on a global scale."
Dr. Merriman comes to HLI most recently from Life Technologies (now a Division of Thermo Fisher Scientific, Inc.), where he was the Lead System Architect for Advanced DNA Sequencing Technology, and co-founder and CSO of the Enterprise Genomics Solutions group. In these roles he established and guided the company's overall strategy and portfolio in sequencing technology, and architected national scale genomics projects. Prior to this, Dr. Merriman was on the faculty of UCLA for 20 years, where he led interdisciplinary research efforts in human genetics, genomic technology, as well as math, physics and engineering. Dr. Merriman has a Ph.D. in Applied Math from The University of Chicago.
Paul Mola, M.S., MSEL, also comes to HLI from Life Technologies, where he was Head of Strategy and Chief of Staff for their Genetic Systems Division. There, he founded their Enterprise Genomics Solutions Group, which established the business model for supporting national scale translational genomics projects, including their first global flagship initiative, the Saudi Human Genome Project in Saudi Arabia. Mola previously served in product development and commercial capacities at Applied Biosystems and Roche Diagnostics. Mola earned an M.S. in Biotechnology from Cochin University of Science and Technology and a MSEL from the University of San Diego, School of Business.
HLI, a privately held company headquartered in San Diego, CA was founded in 2013 by pioneers in the fields of genomics and stem cell therapy. Using advances in genomic sequencing, the human microbiome, proteomics, informatics, computing, and cell therapy technologies, HLI is building the world's most comprehensive database of human genotypes and phenotypes as a basis for a variety of commercialization opportunities to help solve aging related disease and human biological decline. HLI will be licensing access to its database, and developing new diagnostics and therapeutics as part of their product offerings. For more information please visit, www.humanlongevity.com.